Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

Sekine, Akimasa; Satoh, Hiroaki; Baba, Tomohisa; Ikeda, Satoshi; Okuda, Ryo; Shinohara, Tokuko; Komatsu, Shigeru; Hagiwara, Eri; Iwasawa, Tae; Ogura, Takashi; Kato, Terufumi

doi:10.1007/s00280-016-3040-8

Cited by 50 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assessment of the clinical course of IPF has revealed that the incidence rate of AE was 5–15% per year . In addition, the incidence rate of IPF‐AE and mortality is increased in patients with NSCLC and ILD because of chemotherapy treatment . Importantly, in the present study, we found that the incidence rate of IPF‐AE among patients with NSCLC and mGAP stage I IPF, who were treated with a platinum‐doublet as first‐line chemotherapy was similar to that in patients with a general IPF without NSCLC .…”

Section: Discussionsupporting

confidence: 74%

“…19,20 In addition, the incidence rate of IPF-AE and mortality is increased in patients with NSCLC and ILD because of chemotherapy treatment. [1][2][3][4][5][6][7] Importantly, in the present study, we found that the incidence rate of IPF-AE among patients with NSCLC and mGAP stage I IPF, who were treated with a platinum-doublet as first-line chemotherapy was similar to that in patients with a general IPF without NSCLC. 19,20 However, the incidence rate of IPF-AE in patients with NSCLC and mGAP stage II IPF was higher.…”

Section: Discussionsupporting

confidence: 67%

“…Two prospective studies in Japan that evaluated the efficacy and safety of weekly paclitaxel in combination with carboplatin and S‐1 in combination with carboplatin for patients with advanced NSCLC and ILD found that the 1‐year survival rate and median OS were 22% and 33% and 10.6 and 10.4 months, respectively, which were worse than those reported by the prospective Four‐Arm Cooperative Study (FACS) on patients with NSCLC without ILD who were treated with platinum‐based chemotherapy (1‐year survival: 48–60%; median OS: 11.4–14.0 months) . The 1‐year survival rate and median OS of patients with mGAP stage I IPF in the present study were similar to those observed in the FACS trial.…”

Section: Discussionmentioning

confidence: 75%

“…Several studies found that the incidence rate of acute exacerbation (AE) of ILD ranged between 5% and 35% in patients with NSCLC and ILD undergoing chemotherapy. [1][2][3][4][5][6][7][8] We recently reported that mortality after AE in these patients was 20%. 5 It has been previously reported that the incidence rate and severity of AE in ILD were significantly higher in patients with lung cancer with a usual interstitial pneumonia (UIP) pattern on computed tomography (CT) than in those with a non-UIP pattern, 8,9 and 'inconsistent with UIP' patterns on HRCT scanning, which may not be a risk factor for AE in patients with NSCLC and ILD.…”

Section: Introductionmentioning

confidence: 83%

“…Although chemotherapy is often used for patients with NSCLC and ILD, evidence for improved prognosis with chemotherapy is lacking. Several studies found that the incidence rate of acute exacerbation (AE) of ILD ranged between 5% and 35% in patients with NSCLC and ILD undergoing chemotherapy . We recently reported that mortality after AE in these patients was 20% .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease

et al. 2023

View full text Add to dashboard Cite

Background: Lung cancer is frequently accompanied by interstitial lung disease (ILD), and the overall survival (OS) of patients with these comorbidities is poor.Thus, we developed a nomogram for the prediction of the OS of patients with advanced non-small cell lung cancer (NSCLC) and ILD. Patients and Methods: Patients with wild-type gene advanced NSCLC with and without ILD who underwent chemotherapy between 2014 and 2019 were enrolled in the present study. The 0.5-and 1-year progression-free survival (PFS) and overall survival (OS) times of patients with and without ILD were determined using the Kaplan-Meier method. Cox regression was used to assess the prognostic value of clinical factors for patients with ILD. Based on the multivariate regression results, a nomogram for survival prediction was developed. The nomogram was validated using calibration curve. Results: Data from 155 patients with lung cancer and ILD and 118 matched patients with lung cancer alone who were receiving first-line chemotherapy were analyzed. The first-line chemotherapy regimens were paclitaxel + carboplatin, pemetrexed + carboplatin, gemcitabine + carboplatin, and other. The median PFS and OS were significantly shorter in patients with than in those without ILD (3.0 vs. 7.0 months [p < 0.001] and 7.0 vs. 15.0 months (p < 0.001), respectively). Multivariate analysis showed that the lymphocyte count (hazard ratio [HR] 2.38; 95% confidence interval [CI], 1.44-3.94; p = 0.01), partial pressure of oxygen (PaO 2 ; HR, 1.37; 95% CI, 1.03-1.82; p = 0.03), and chemotherapy regimen were independently associated with prognosis. The nomogram showed good discriminatory ability [C-index = 0.69 (95% CI, 0.49-0.82)]. Calibration curves showed that predicted and actual prognoses were consistent. Conclusion: This nomogram can aid the prediction of the OS of patients with advanced NSCLC and ILD. How to cite this article: Xiu W, Zheng J, Zhou Y, et al. A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.

show abstract

The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

Masuda

Hirano

Horimasu

et al. 2017

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

Cited by 50 publications

References 35 publications

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non‐small cell lung cancer

A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease

The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

Contact Info

Product

Resources

About